MedTech Global Insights

The U.S. FDA has finalized its rule to regulate laboratory-developed tests (LDTs) as medical devices, ending decades of enforcement discretion. This landmark decision imposes significant new requirements on clinical laboratories, aligning them with traditional IVD manufacturers and creating a new set of complex challenges for market access and compliance. This shift will require labs to navigate a multi-year transition into full FDA compliance, including premarket reviews, quality system regulations, and post-market reporting. A university lab with a novel cancer diagnostic, for instance, now faces the daunting task of building a 510(k) submission and implementing a manufacturing-grade quality system, potentially stalling their innovation without expert regulatory guidance. Key Takeaways: - How does the FDA's five-year phase-in plan for LDTs affect my lab's current operations? - What are the first steps to transition from CLIA compliance to FDA Quality System Regulation? - Does my existing LDT qualify for any of the FDA's proposed grandfathering clauses? - How can I build a regulatory strategy to prepare for a 510(k) submission? - What new responsibilities will my lab have for post-market surveillance and adverse event reporting? - Will this new rule create new opportunities for partnership with traditional IVD manufacturers? - How can we leverage our existing clinical data to support a future premarket submission? To learn more about navigating the new U.S. regulatory landscape or other global markets, contact us at info@pureglobal.com, visit https://pureglobal.com/, or access our FREE AI tools and medical device database at https://pureglobal.ai/.

This week, we dive into the new medical device regulatory reliance pilot program launched between Malaysia and Thailand. This collaboration creates a powerful fast-track for market access in the ASEAN region, allowing companies to leverage an approval in one country to accelerate registration in the other, but the pathway is filled with critical nuances. We explore how this program fundamentally changes the strategic map for Southeast Asia. It's a game-changer for companies that previously faced the costly and time-consuming process of separate submissions, but success requires more than just a prior approval. **Case In Point:** A US-based startup with a novel Class B device secured approval in Thailand. They thought the new reliance program meant a simple, automatic entry into Malaysia. They were wrong. Their submission was rejected due to a failure to meet Malaysia's specific labeling and local representation requirements, a costly mistake that could have been avoided and delayed their market entry by months. **In this episode, you will learn:** - What specific device classes are eligible for the Malaysia-Thailand reliance pilot? - How does this reliance pathway differ from other international programs like MDSAP? - What are the top three documentation mistakes that can get your application rejected? - Do you still need a separate local authorized representative in both countries? - How does this pilot affect post-market surveillance and vigilance reporting? - What is the expected timeline and cost savings compared to traditional submissions? - Could this program be a model for a future, unified ASEAN regulatory framework? For more information, contact us at info@pureglobal.com, visit https://pureglobal.com/, or access our FREE AI tools and medical device database at https://pureglobal.ai/.

Last week, the U.S. FDA began strict enforcement of new cybersecurity rules for medical devices, catching many global manufacturers by surprise. This sudden shift requires a complete software bill of materials (SBOM) and a proactive security plan, leading to submission rejections and significant market delays for unprepared companies. This episode of MedTech Global Insights dives into the immediate impact of the FDA's new stance. We break down what this means for device makers, from startups to enterprise leaders, and explore the strategic adjustments necessary to navigate this new, complex regulatory landscape and avoid costly mistakes at the finish line. **Key Takeaways:** * What are the three most common deficiencies in a cybersecurity submission that lead to an immediate FDA rejection? * How can you create a Software Bill of Materials (SBOM) for a legacy device without rebuilding it from scratch? * Is your post-market surveillance plan truly proactive, or just a reactive promise? * How does the FDA's cybersecurity enforcement compare to upcoming regulations in the EU? * What tools and processes must be integrated into your Quality Management System to ensure compliance? * Can you leverage your existing technical file to meet these new, demanding requirements? * What are the unwritten expectations from FDA reviewers when they assess your cybersecurity file? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.

The U.S. FDA has drawn a new line in the sand for MedTech innovators. With its "refuse to accept" policy now in effect for 510(k) submissions lacking robust cybersecurity measures, the rules for market entry have fundamentally changed. This episode breaks down the new mandatory requirements, including the crucial Software Bill of Materials (SBOM) and post-market surveillance plans that are now non-negotiable. We explore the immediate and long-term strategic impacts on MedTech companies. This isn't just another regulatory hurdle, it's a paradigm shift that redefines the responsibilities of a medical device manufacturer, forcing a convergence of clinical safety and digital security. A leading cardiac monitoring company just had its latest 510(k) submission for a new wireless ECG device stopped cold. The reason? Not a failure in clinical trials, but an incomplete Software Bill of Materials and a weak plan for future cybersecurity monitoring. This costly delay highlights a critical new pain point: your go-to-market strategy is now as dependent on your cybersecurity framework as it is on your clinical data. Key Takeaways: - What is a Software Bill of Materials (SBOM) and why is it now a critical submission component? - How can you develop a post-market surveillance plan that satisfies the FDA's new expectations? - Are the new cybersecurity rules inadvertently creating a barrier for smaller, innovative startups? - What new expertise is required for your regulatory and R&D teams to navigate this landscape? - How will this aggressive stance from the FDA influence regulatory bodies in Europe and Asia? - Does your current Quality Management System adequately address cybersecurity lifecycle management? - What are the key liabilities if a vulnerability is discovered after your product is on the market? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/. You can also visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.

The European Union has once again extended the transition deadlines for the In Vitro Diagnostic Regulation (IVDR), creating both relief and confusion for diagnostic manufacturers. This episode of MedTech Global Insights breaks down what this latest delay really means for the industry and your business strategy. We go beyond the headlines to explore the strategic dilemmas facing companies. Is this extension a lifeline or a trap that penalizes proactive companies that invested millions to be ready on time? We explore the real-world impact on a high-risk device maker and the tough decisions they now face, highlighting the critical need for an agile regulatory strategy in an unstable environment. This week's key takeaways: 1. Why was the IVDR deadline extension necessary to prevent a public health crisis? 2. What are the specific new proposed transition dates for high-risk Class D and C devices? 3. How does this delay create a competitive disadvantage for companies that were already prepared? 4. Is the Notified Body bottleneck getting better or worse, and what does it signal for future regulations? 5. What immediate strategic questions should your leadership team be asking right now? 6. How can you leverage this extra time to strengthen your technical dossier instead of just waiting? 7. Does this extension affect devices that are already IVDR certified? 8. What are the hidden costs of prolonged regulatory uncertainty for your business? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.

In the last week of March, the US FDA dramatically escalated its cybersecurity requirements for wirelessly connected medical devices, creating new, complex hurdles for manufacturers. This move signals a major shift from passive checklists to demands for proactive threat management, catching many international companies unprepared and threatening their access to the world's largest MedTech market. This change is not just about documentation; it's about a fundamental re-engineering of a product's security architecture and post-market responsibilities. For companies, especially those outside the US, the new unspoken rules can lead to sudden submission rejections, costly delays, and significant loss of revenue, turning a planned product launch into a regulatory crisis. A prime example is a German diagnostics firm whose cutting-edge remote monitoring system was just rejected by the FDA. Their critical error? Submitting a 'reactive' cybersecurity plan. They now face a scramble to redesign their system to include a dynamic threat model and a full Software Bill of Materials (SBOM), a complex challenge jeopardizing their entire US expansion. 本期干货 * Why is a Software Bill of Materials (SBOM) suddenly a deal-breaker for FDA submissions? * What are the top vulnerabilities the FDA is now targeting in connected devices? * How can you demonstrate that your post-market surveillance plan is 'proactive'? * Do these new, stricter requirements apply to devices already on the market? * What are the hidden engineering costs of implementing continuous threat modeling? * How do the FDA’s new expectations compare to the EU's cybersecurity requirements under MDR? * What specific documentation is now essential to prove a secure product development framework? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.

This week on MedTech Global Insights, we dissect the FDA's groundbreaking announcement of a new AI-powered platform for monitoring adverse events. This move signals a seismic shift from reactive to proactive post-market surveillance, creating a new set of complex challenges for medical device manufacturers. We explore the hidden data burdens this new system imposes. For instance, a European manufacturer of a neurological device, successful in the US market, suddenly faces an FDA inquiry. The trigger? Not a formal report, but an AI-detected pattern of patient complaints about minor side effects on a public health forum. Their existing compliance team is unequipped to handle, analyze, or even monitor such unstructured data, putting their market access at immediate risk. Key Takeaways: * What are the top three unconventional data sources the new FDA platform will likely monitor? * How will AI-driven alerts change the definition of a "potential" adverse event? * What new skillsets will regulatory affairs teams need to manage this new reality? * Why might smaller companies be at a disadvantage, and what can they do to compete? * How can you pressure-test your current post-market system against this new AI threat? * What is the first step in building an internal system to mirror the FDA's new capabilities? * Could this new U.S. system set a precedent for other global regulatory bodies? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/. For free AI tools and a comprehensive medical device database, visit https://pureglobal.ai/.

The U.S. FDA has just redefined the rules for AI-powered medical software, shifting from one-time approvals to demanding continuous, real-world performance data. This new 'Lifecycle Assurance' approach signals a global trend towards total product lifecycle regulation, creating urgent challenges for MedTech innovators. This episode of MedTech Global Insights unpacks what this means for device manufacturers. We explore how this regulatory shift impacts market access, operational costs, and investment, forcing companies to move beyond passive complaint logging to a strategy of proactive, global data surveillance to maintain their place in the market. **Featured Case:** A successful German MedTech scale-up with FDA clearance for their AI stroke detection software is suddenly at risk. The new FDA mandate requires continuous performance data across diverse populations, a capability they never built. Their market access and next funding round are now in jeopardy. **Key Takeaways From This Episode:** * Why is the FDA suddenly focusing on 'Lifecycle Assurance' for AI/ML devices? * What specific real-world data are regulators now demanding post-approval? * How does the FDA's new stance align with regulatory trends in the EU and Asia? * Is your current post-market surveillance plan now obsolete? * What are the hidden infrastructure costs of maintaining compliance for SaMD? * How can a startup build a global compliance strategy from day one without breaking the bank? * What are the key differences between reactive and proactive surveillance? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.

The U.S. FDA just reclassified a key category of optical diagnostic devices, a move that reshaped the competitive landscape for the entire ophthalmic tech industry last week. This is not just a minor regulatory update; it is a fundamental shift that could either fast-track your product to market or unleash a flood of new, agile competitors. In this episode, we dissect the FDA's final order and its strategic implications. We explore the critical pivot required for both established players and new market entrants, detailing the new opportunities in the 510(k) pathway and the hidden compliance challenges buried in the new "special controls." A case in point: Imagine your company has a next-generation optical diagnostic device stuck in the expensive, multi-year PMA process. Suddenly, the FDA reclassifies your device category, opening a much faster 510(k) pathway. How do you scrap your old plans and build a new submission strategy in weeks, not years, to beat new competitors to the prize? Key Questions Answered: - What does the FDA's new reclassification order for optical devices truly mean? - How can you determine if your specific product is affected by this change? - What are the new "special controls" and how do they impact your technical file? - For startups, does this new rule open a backdoor to the U.S. market? - For established companies, how does this event disrupt your current market position? - What is the fastest way to pivot from a PMA to a 510(k) strategy? - How could this reclassification impact future reimbursement and commercialization? - What are the key compliance risks you need to address immediately? To learn more about navigating the global regulatory environment, contact us at info@pureglobal.com or visit https://pureglobal.com/. For FREE AI tools and a free medical device database, visit https://pureglobal.ai/.

The U.S. FDA has quietly dropped a bombshell on the AI medical device industry. A new draft guidance is set to redefine what "post-market surveillance" means for software, creating a complex and costly new reality for innovators. This episode dives into the critical shift from focusing on pre-market approval to the necessity of continuous, real-world performance monitoring. We explore the challenge through the lens of a startup with a newly cleared AI diagnostic tool. The celebration of market approval is short-lived as they now face the daunting and expensive task of tracking their algorithm's performance in real-time. This isn't just a compliance headache; it's a potential threat to their business model and a new barrier to innovation. Key Takeaways: - What exactly is "algorithmic drift" and why is the FDA suddenly so concerned about it? - How will the new post-market data collection rules impact the budgets and survival of MedTech startups? - Does this new regulatory stance give larger, established companies an unfair advantage? - What are the hidden data privacy risks involved in continuous AI performance monitoring? - How might this U.S. policy shift influence regulators in Europe and Asia in the coming year? - What proactive strategies can software medical device companies adopt right now to prepare? - Is your current technical documentation prepared for this new lifecycle approach to regulation? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.

In this episode of MedTech Global Insights, we unpack the most significant regulatory shift in Southeast Asia this year. The costly and time-consuming process of seeking individual device approvals in each country is being replaced by a powerful new trend: regulatory reliance. We dive into the new pilot program between Malaysia and Thailand that is creating an expedited pathway for market access. Imagine your company just spent two years and a significant budget getting your device approved in one country. Now you face the same mountain in the neighboring market. What if there was a way to use your existing approval to cut the next timeline in half? This is the reality that new ASEAN reliance programs are creating, but navigating them requires insider knowledge. This week's insights: - What exactly is the new Malaysia-Thailand regulatory reliance pilot program? - How does this "shortcut" actually accelerate your market entry process? - Which specific device classes are most likely to benefit? - Is this a one-off deal or part of a larger strategic trend in Southeast Asia? - How can approvals from the US or EU be leveraged in this new framework? - What are the hidden risks or documentation requirements for using these pathways? - How does this fundamentally change the strategy for MedTech expansion into Asia? - Which country's approval now offers the best "gateway" to the broader ASEAN region? For a deeper conversation on building your global strategy, contact us at info@pureglobal.com or visit https://pureglobal.com/. You can also explore our FREE AI tools and medical device database at https://pureglobal.ai/.

The European Union is taking decisive action to combat the critical shortage of medical devices, a problem that has plagued its healthcare systems since the rollout of MDR. This episode unpacks the European Commission's new proposal for a mandatory six-month notification period for discontinuing devices, and what it means for manufacturers. This isn't just another form to fill out. it's a fundamental shift in market responsibility that directly impacts product lifecycle management, supply chain forecasting, and your competitive position. We explore the strategic challenges and opportunities this new era of mandatory transparency creates for MedTech companies operating in the EU. A French manufacturer of a critical diagnostic assay decides to discontinue the product due to low margins and high MDR compliance costs. Their plan was to quietly phase it out within three months. Suddenly, they are faced with the new six-month mandatory notification rule, forcing them to continue production at a loss, manage difficult conversations with distributors, and alert competitors to their exit strategy far earlier than intended, creating a significant strategic dilemma. Key Takeaways: - What triggers the mandatory six-month shortage notification requirement in the EU? - How does this new rule change the financial calculation for discontinuing a legacy product? - What specific information must manufacturers now provide to competent authorities? - How can you turn supply chain transparency into a competitive advantage in the EU market? - What are the legal and commercial risks of failing to comply with this new proposal? - How should this rule affect your product portfolio and end-of-life strategies? - Does this new EU rule align with or diverge from supply notification rules in the US or other markets? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.

This week, MedTech Global Insights explores the seismic shift in European regulations for AI-powered medical devices. A major EU Notified Body has dropped a new, mandatory cybersecurity guidance document, sending shockwaves through the industry by demanding retroactive compliance. We unpack what this means for manufacturers, from agile startups to global giants. We explore the stringent new requirements for a Software Bill of Materials (SBOM) and penetration testing, and the immediate compliance scramble that is turning a regulatory update into a high-stakes business challenge. Consider this case: a promising MedTech company's leading AI diagnostic software, already on the market, is suddenly facing delisting. This is the reality for innovators who now must prove end-to-end digital safety based on rules that didn't exist when they got their approval. Their pain is a warning for all that market access is not guaranteed to last. Key Takeaways: - Why is a Software Bill of Materials suddenly a deal-breaker for EU market access? - What are the three biggest cybersecurity vulnerabilities that regulators are targeting now? - Could your existing CE mark be invalidated by a post-market guidance update? - What are the hidden operational costs of this new compliance scramble? - How does this shift the definition of market-readiness for all software-based medical devices? - Is this new regulation a barrier to entry, or an opportunity for prepared firms? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/. You can also visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.

The FDA has officially replaced the long-standing QSIT inspection model with a new approach under the Quality Management System Regulation (QMSR). This shift towards harmonization with ISO 13485 introduces a more holistic, risk-based auditing process, catching many MedTech manufacturers off guard and rendering their old preparation methods obsolete. This episode of MedTech Global Insights dives into what this change really means for your operations. We explore the critical differences between the old and new inspection techniques and the immediate impact on quality assurance teams. **Case In Point:** A manufacturer of infusion pumps, confident in their CAPA and Design Control subsystems, recently faced a QMSR audit. Instead of following the old checklist, the inspector focused entirely on the risk management files and post-market complaint data for a single product line, uncovering gaps in their risk-to-complaint process that the previous QSIT audit never would have flagged. **In This Episode, We Ask:** - Is your quality system truly integrated, or just a collection of compliant subsystems? - How does the new QMSR inspection approach change the way you should manage suppliers? - What are the key differences in documentation an investigator will now demand? - Does your current risk management process stand up to a full product lifecycle trace audit? - How can you leverage your ISO 13485 certification for the new FDA inspections? - What immediate changes should you make to your internal audit program? - Are your teams trained to speak to processes and risks, not just procedures? To ensure your quality system is ready for this new era, contact us at info@pureglobal.com or visit https://pureglobal.com/. For free AI tools and access to a comprehensive medical device database, visit https://pureglobal.ai/.

This week, MedTech Global Insights dives into the most significant U.S. regulatory shift of 2026: the FDA's new Quality Management System Regulation (QMSR). We uncover why this is far more than a simple alignment with international standards and exposes a new level of corporate liability. The episode reveals how FDA inspectors now have unprecedented access to high-level management review meetings. We explore a real-world case where a company's internal decision to 'monitor' a component risk, once a private discussion, is now a transparent record for regulators, potentially creating massive legal and financial exposure after a single patient incident. Key Takeaways: - Why is the FDA's new QMSR more than just a paperwork update? - What specific internal documents are now exposed to FDA inspectors for the first time? - How does this rule change the personal liability of your executive team? - Is your current "quality culture" strong enough to withstand direct regulatory scrutiny? - What's the number one mistake companies are making in their management review meetings right now? - How can you turn this new regulatory pressure into a competitive advantage? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.

The FDA's "honeymoon phase" for medical device cybersecurity is over. In this episode, we dissect the agency's heightened scrutiny on premarket submissions, moving beyond simple documentation to active verification. We explore the new, unwritten rules manufacturers must follow to avoid costly rejections. We look at the case of a company whose 510(k) submission was delayed for months. Despite providing a complete Software Bill of Materials (SBOM), they were rejected because a common open-source library had a vulnerability. Their pain point was the failure to provide a VEX document to prove the vulnerability was not exploitable in their device, a detail that has become a silent requirement for approval. Key Takeaways: - Why is a complete SBOM no longer sufficient for an FDA submission? - How is the FDA using public databases to challenge your device's security in real-time? - What is a VEX document and how can it rescue your submission from an almost certain rejection? - Can you prove your Secure Product Development Framework is truly "built-in" and not just "bolted-on"? - What is the most critical question to answer about your vulnerability management plan? - How do you address the ticking time bomb of legacy device security? - What are the three essential components of a security narrative that the FDA now expects to see? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/. Explore our FREE AI tools and medical device database at https://pureglobal.ai/.

The FDA has drawn a new line in the sand for medical device market access, and non-compliance means immediate rejection. With the full implementation of Section 524B of the FD&C Act, robust cybersecurity documentation is no longer optional for any 510(k) submission of a connected "cyber device." This episode breaks down the critical new requirements that are already impacting market entry timelines. We explore the costly lesson of a European AI startup whose promising 510(k) submission was instantly rejected with a "Refuse to Accept" letter. Their mistake wasn't in the clinical data, but in their failure to provide a Software Bill of Materials (SBOM) and a post-market vulnerability plan, causing a six-month delay and putting their funding at risk. This is the new reality of entering the US market. This week's insights: - What is the FDA's new line in the sand for medical device cybersecurity? - Is your device a "cyber device" and what does that legally require now? - What is a Software Bill of Materials (SBOM) and why is it non-negotiable? - How can a simple documentation gap lead to a costly "Refuse to Accept" letter? - What post-market monitoring plan does the FDA now expect to see *before* you go to market? - Why is your engineering team's process now a critical part of your regulatory submission? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.

This week on MedTech Global Insights, we dissect the groundbreaking new draft guidance from the U.S. FDA on AI and Machine Learning medical devices. This pivotal announcement introduces new requirements for adaptive algorithms, fundamentally changing the regulatory landscape for software as a medical device (SaMD) manufacturers worldwide. We explore what the new "Predetermined Change Control Plan" means for your technical dossier, validation strategies, and post-market surveillance. We break down the ripple effects this will have on other major markets and discuss the strategic adjustments companies must now consider to ensure successful global market access. Imagine a promising European startup with a revolutionary AI diagnostic tool, fully certified for the EU market. They've invested millions and are ready for U.S. expansion. Suddenly, the new FDA guidance renders their existing validation data insufficient. They now face a costly, time-consuming overhaul of their entire regulatory strategy, putting their funding and market lead at risk. Key Takeaways: - What are the three biggest changes in the new FDA AI/ML guidance? - How does a "Predetermined Change Control Plan" work in practice? - Will my existing clinical validation data be accepted under these new U.S. rules? - How does this impact MedTech companies based outside of the United States? - What are the new expectations for post-market surveillance of learning algorithms? - Is the European Union likely to adopt a similar framework for AI devices? - How can startups navigate these new regulatory hurdles without a massive budget? - What's the key difference between the FDA's approach and the EU's AI Act for MedTech? For more insights, contact us at info@pureglobal.com or visit https://pureglobal.com/. You can also access our FREE AI tools and medical device database at https://pureglobal.ai/.

This week, MedTech Global Insights explores a critical challenge for international manufacturers entering the U.S. market. We analyze the recent case of a leading Japanese robotics firm whose 510(k) submission for an innovative surgical system was rejected by the FDA. The cause was not clinical failure, but non-compliance with new digital submission standards and cybersecurity protocols. This episode breaks down the costly administrative and technical hurdles that can blindside even the most advanced MedTech companies. We reveal how the FDA’s mandatory eSTAR portal and its stringent cybersecurity requirements are acting as a new gatekeeper, making regulatory strategy more complex than ever. This is a must-listen for any company planning a U.S. product launch. Key Takeaways: * What exactly is a Software Bill of Materials (SBOM) and why is it now mandatory for an FDA submission? * How can you pre-validate a digital submission to avoid an automatic Refusal to Accept? * Are your current cybersecurity protocols strong enough to meet the FDA's 2026 standards? * What are the most common formatting errors that cause an eSTAR submission to be rejected? * How can foreign companies align their quality management systems with U.S. digital requirements? * Can a digital submission rejection negatively impact investor confidence and launch timelines? * Your 510(k) was refused; what is the very first step you should take to recover? * How does a U.S. agent or local representative help prevent these kinds of submission failures? For more insights, contact us at info@pureglobal.com or visit https://pureglobal.com/. Explore our FREE AI tools and medical device database at https://pureglobal.ai/.

This week on MedTech Global Insights, we dive into a crucial, under-the-radar development from the U.S. FDA. We explore the recent clearance of an AI-powered triage tool for stroke detection and what this single approval reveals about the future of AI regulation in American healthcare. We move beyond the hype of algorithms and predictive accuracy to uncover the real challenges and expectations the FDA has for MedTech innovators. This episode is essential for anyone developing or seeking approval for an AI-enabled medical device. Case In Point: A new AI tool can now analyze a non-contrast CT scan and flag a potential stroke case in seconds, pushing it to the front of a busy radiologist's queue. But the manufacturer’s biggest challenge wasn’t proving the AI was accurate. It was proving the entire system was safe, secure, and seamlessly integrated into the chaotic hospital environment. How do you prepare your regulatory submission for this level of scrutiny? This week's key questions: 1. Why is the FDA's latest AI clearance more about workflow than the algorithm itself? 2. What are the key cybersecurity risks the FDA expects you to address for connected AI devices? 3. How can you demonstrate effective 'human factors' engineering in your submission? 4. What do the FDA's updated AI resource pages signal for future regulatory requirements? 5. Why is a post-market surveillance plan now critical for getting initial approval? 6. How does this impact foreign manufacturers trying to enter the U.S. market? 7. Are you prepared for the shift from one-time clearance to continuous performance monitoring? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.